Fundus-first Laparoscopic Cholecystectomy

NCT ID: NCT07137546

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

174 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bile duct injury (BDI) remains the most feared complication of laparoscopic cholecystectomy, particularly in difficult gallbladder cases. The fundus-first technique has emerged as a potentially safer alternative to classical laparoscopic cholecystectomy for challenging cases. This single-center, prospective, randomized controlled trial compared the efficacy and safety of fundus-first laparoscopic cholecystectomy (FF-LC) versus classical laparoscopic cholecystectomy (C-LC) in 174 patients with difficult gallbladder characteristics. The primary outcome was bile duct injury rate. Secondary outcomes included conversion to open surgery, operative parameters, and postoperative complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bile duct injury (BDI) rates remain 0.3-1.5% in difficult gallbladders. FFLC avoids early dissection near critical structures, potentially lowering BDI risk.

This randomized controlled trial aims to compare the safety and efficacy of fundus-first (FF) versus classical (Calot-first) laparoscopic cholecystectomy techniques in patients with difficult gallbladders. The study will evaluate perioperative outcomes, conversion rates, complications, and operative time between the two surgical approaches. Based on recent evidence suggesting an improved safety profile with the fundus-first technique, we hypothesize that the FF approach will demonstrate reduced bile duct injury rates and improved surgical outcomes in difficult cases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholecystitis Acute Cholecystitis Pericholecystic Abscess

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Surgeons are not blinded due to the intervention's nature; data collectors, assessors, and analysts are blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fundus-First Laparoscopic Cholecystectomy ( FFLC)

Laparoscopic cholecystectomy starting dissection at the gallbladder fundus, progressing retrograde toward the cystic duct/artery. Critical View of Safety (CVS) confirmed before duct division.

Group Type EXPERIMENTAL

Fundus-First Laparoscopic Cholecystectomy ( FFLC)

Intervention Type PROCEDURE

* Standard 4-port laparoscopic setup
* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)
* Dissection begins at gallbladder fundus
* Peritoneum incised from infundibulum to fundus along liver bed
* Gallbladder dissected from fundus toward infundibulum
* Cystic artery and duct identified and divided last
* Critical view of safety achieved before vessel division

Classical Laparoscopic Cholecystectomy (CLC)

The standard "critical view of safety" technique (anterior-posterior dissection of Calot's triangle first).

Group Type ACTIVE_COMPARATOR

Classical Laparoscopic Cholecystectomy (CLC)

Intervention Type PROCEDURE

* Standard 4-port laparoscopic setup
* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)
* Dissection begins at Calot's triangle
* Critical view of safety achieved first
* Cystic artery and duct divided before gallbladder bed dissection
* Gallbladder dissected from liver bed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fundus-First Laparoscopic Cholecystectomy ( FFLC)

* Standard 4-port laparoscopic setup
* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)
* Dissection begins at gallbladder fundus
* Peritoneum incised from infundibulum to fundus along liver bed
* Gallbladder dissected from fundus toward infundibulum
* Cystic artery and duct identified and divided last
* Critical view of safety achieved before vessel division

Intervention Type PROCEDURE

Classical Laparoscopic Cholecystectomy (CLC)

* Standard 4-port laparoscopic setup
* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)
* Dissection begins at Calot's triangle
* Critical view of safety achieved first
* Cystic artery and duct divided before gallbladder bed dissection
* Gallbladder dissected from liver bed

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80 years
* Symptomatic cholelithiasis or cholecystitis requiring laparoscopic cholecystectomy (elective or emergency)
* Difficult gallbladder characteristics: Acute cholecystitis (Tokyo Guidelines 2018 Grade II/III), wall thickness \>4 mm on US, pericholecystic fluid, impacted stone in Hartmann's pouch/cystic duct, previous upper abdominal surgery, BMI \>30 kg/m², ≥3 previous cholecystitis episodes, contracted gallbladder, Mirizzi syndrome Type I/II, empyema, severe pericholecystic adhesions on imaging, suspected anatomical variations
* The American Society of Anesthesiologists (ASA) physical status I-III
* Suitable for laparoscopic approach
* Informed consent

Exclusion Criteria

* Suspected gallbladder malignancy
* Choledocholithiasis requiring endoscopic intervention
* Mirizzi syndrome Grade III-IV
* Gallbladder perforation with generalized peritonitis
* Pregnancy or lactation
* Contraindications to laparoscopy (severe cardiopulmonary disease, coagulopathy)
* Previous biliary or hepatic surgery
* Cirrhosis with portal hypertension
* Active coagulopathy
* Patient refusal
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Minia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Saleh Khairy Saleh MD

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Saleh K Saleh, MD

Role: PRINCIPAL_INVESTIGATOR

Minia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Liver and GIT hospital / Minia university

Minya, Minya Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1131/04/2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.